U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 13:39:47 GMT 2023
Edited
by admin
on Sat Dec 16 13:39:47 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
SWS48LJU3T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIRENTELIMAB
INN   USAN  
Official Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN SIALIC ACID-BINDINGE IG-LIKE LECTIN 8) (HUMAN-MUS MUSCULUS MONOCLONAL AK002 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL AK002 .KAPPA.-CHAIN, DIMER
Common Name English
ANTOLIMAB
Common Name English
LIRENTELIMAB [USAN]
Common Name English
AK-002
Code English
MONOCLONAL ANTIBODY AK002
Common Name English
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS SIALIC ACID-BINDING IG-LIKE LECTIN 8 (SIALOADHESIN FAMILY MEMBER 2, SIGLEC-8, SAF-2))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (VH (HOMO SAPIENS IGHV3-66*01 (79%) (IGHD)-IGHJ5*01 (91%)/MUS
Common Name English
AK002
Code English
lirentelimab [INN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 628417
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
FDA ORPHAN DRUG 623017
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
FDA ORPHAN DRUG 668818
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
FDA ORPHAN DRUG 693519
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C129591
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
PRIMARY
INN
11511
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
PRIMARY
CAS
2283348-97-8
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
PRIMARY
USAN
GH-173
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
PRIMARY
WIKIPEDIA
Lirentelimab
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
PRIMARY
FDA UNII
SWS48LJU3T
Created by admin on Sat Dec 16 13:39:47 GMT 2023 , Edited by admin on Sat Dec 16 13:39:47 GMT 2023
PRIMARY
From To
1_22 1_95
1_147 1_203
1_223 3_213
1_229 2_229
1_232 2_232
1_264 1_324
1_370 1_428
2_22 2_95
2_147 2_203
2_223 4_213
2_264 2_324
2_370 2_428
3_23 3_87
3_133 3_193
4_23 4_87
4_133 4_193
Glycosylation Type MAMMALIAN, AFUCOSYLATED
Glycosylation Link Type Site
N 1_300
N 2_300
Related Record Type Details
SIALIC ACID-BINDING IG-LIKE LECTIN 8
TARGET->LIGAND
AK002 is an IgG1 monoclonal antibody with demonstrated cytotoxicity (ADCC) against eosinophils and mast cells.
Related Record Type Details
LIRENTELIMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966